LimmaTech Biologics AG from the Greater Zurich Area has agreed a cooperation with Griffith University in Brisbane, the capital city of the Australian State of Queensland. According to a press release, the partnership is centered around licensing a technology developed at the university, which LimmaTech Biologics is keen to use to advance the development of new vaccines. The focus here is on vaccines that prevent diseases with significant unmet medical need caused by emerging antibiotic resistant strains.
First of all, LimmaTech Biologics intends to advance the development of the world’s first vaccination against gonorrhea, which the biopharmaceutical company claims is the second most common sexually transmitted infection around the world. Left untreated, gonorrhea can have serious consequences, including infertility in women and blindness in newborn children.
“The bacterium causing gonorrhea has developed resistance to almost all the antibiotics used to treat the disease. The absence of a vaccine and the emergence of antibiotic-resistant gonococcal strains poses an urgent public health threat”, explains Kate Seib, Professor at Griffith University, in the press release. Seib hopes that the cooperation with LimmaTech Biologics can play a part in helping to solve a global problem.
LimmaTech Biologics was founded in 2015 as a spin-off from GlycoVaxyn after the latter was taken over by the UK pharma giant GlaxoSmithKline. The company is headquartered in Schlieren and is a member of the Bio-Technopark Schlieren-Zurich.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space